French financial crime authorities on Tuesday morning carried out a surprise raid at the Paris headquarters of global pharmaceuticals major Sanofi, as part of an ongoing investigation into alleged tax fraud and money laundering. The probe centers around a complex financing arrangement—specifically, a loan extended to Sanofi by French multinational bank Societe Generale more than a decade ago. According to officials, over 30 agents from the financial prosecutor’s office participated in the search operation.
Sanofi has formally confirmed the raid and stated that it is fully cooperating with investigators.
Probe Focuses on a Corporate Loan Structure Offered by Société Générale
According to a Sanofi spokesperson, the investigation pertains to a loan structure arranged during one of the company’s major acquisitions. At that time, Société Générale had offered a specific financing mechanism that, according to French authorities, is now under scrutiny for possible misuse.
Sanofi maintains that the mechanism was a standard corporate financing arrangement, widely used by several blue-chip companies, and asserts that it has “complied with all applicable laws and regulations.”
Earlier Raids at Société Générale’s Offices in Paris and Luxembourg
Reports from Le Monde indicate that the French National Financial Prosecutor’s Office (PNF) had previously conducted raids in June 2025 at Société Générale’s offices in Paris and Luxembourg. Investigators are examining whether the financing arrangements facilitated tax evasion or a sophisticated laundering system.
The investigation does not involve Sanofi alone. Other major corporations—including dairy giant Lactalis and insurance and asset management firm AXA—also reportedly used similar financing structures offered by Société Générale. Authorities are now scrutinizing whether these mechanisms enabled companies to bypass tax liabilities or conceal taxable assets.
Case Registered Under “Money Laundering of Tax Fraud” and “Criminal Conspiracy”
The ongoing probe was initiated in January 2024 by the PNF. The case includes serious allegations such as money laundering of tax fraud, criminal conspiracy, and the potential use of cross-border financial arrangements to evade regulatory oversight.
Investigators are examining multiple large-scale financial deals and acquisitions from previous years, assessing whether companies intentionally structured payments or loans to reduce taxable income or hide financial flows.
Sanofi has reiterated that it will protect its legal rights and maintain full cooperation until the probe reaches its conclusion.
Sanofi Already Under EU Scrutiny Over Vaccine Market Practices
The latest raid adds to growing regulatory headwinds for Sanofi, which has already been facing a separate investigation by the European Commission. This earlier probe revolves around concerns of market abuse, anti-competitive practices, and Sanofi’s dominant position in the European vaccines market.
In September 2025, European regulators conducted unannounced inspections at Sanofi facilities in both Germany and France. Authorities suspect that certain business practices may have limited competition or influenced vaccine market dynamics.
The dual investigations underscore increasingly strict oversight of major pharmaceutical companies in Europe.
Tighter Global Scrutiny on the Pharma Industry
The developments reflect a broader international trend of heightened scrutiny of the pharmaceutical sector’s financial transparency, tax governance, and market behavior. Regulatory bodies across Europe and beyond are now more aggressively examining whether multinational corporations are using complex financing networks, cross-border deals, or tax structures to avoid compliance.
Governments are particularly focused on ensuring that essential sectors—like pharmaceuticals—adhere to strict corporate governance, especially given their scale, global influence, and public health significance.
Sanofi’s Official Position
In its official statement, Sanofi emphasized:
“Sanofi considers it has complied with all applicable laws and regulations. The Group reserves all its rights and will cooperate fully with the authorities.”
However, until the PNF concludes its investigation, questions are likely to persist regarding the company’s financial arrangements and historical dealings.
